Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

remaining outstanding convertible notes with common stock upon maturity, the Company believes it has sufficient funds to execute its current business plans for at least the next twelve months.

Conference Call

Novavax's management will host its quarterly conference call at 10:00 a.m. eastern time today. The live conference call will be accessible via Novavax's website at www.novavax.com under Investor/Events or by telephone at 1 (866) 225 4091 (U.S. or Canada) or 1-703-639-1128 (International). An archive of the conference call will be available on Novavax's website approximately one hour after the event for 90 days. A replay of the webcast will be available on the website for 90 days after the call and a replay of the conference call will also be available by telephone beginning May 8, 2009 at 1:00 pm through May 13, 2009 at 11:59 pm. To access the replay, dial 1 (888) 266 2081 and enter passcode 1357908.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 One ... regenerative medicine is an inadequate vascular supply. Nutrient ... and decellularized tissues is critical for successful regeneration ... attempted to mitigate deficiencies in vascularization and promote ... scaffold bioactivity, optimizing scaffold design and architecture, and ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
(Date:8/19/2014)... In November 2012, the European Union (EU) mandated use ... a new PSUR – responding to the increasing need to ... drug. Adopted in many regions, the main objectives of the ... and critical analysis of new or emerging information on the ... evidence of the potential benefits of a drug; and , ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... M plus potential annual revenue to ProMetic derived from first ... hyperimmune product - Kedrion ... technology in Kedrion,s ... process, MONTREAL, Feb. 26 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc.,("ProMetic") (TSX:PLI) announced today ...
... pathogen detection capabilities for air samples using an advanced ... ... Systems Inc.,(MFSI) today announced that it has signed agreements with ... Applera Corporation,business, and Hamilton Sundstrand, a United Technologies (NYSE: ...
... up from $42 ... product sales expected with delivery of ABthrax(TM) to ... - First Albuferon(R) Phase 3 data expected late 2008 -, - Enrollment completed in randomized Phase 2 ... myeloma -, ...
Cached Biology Technology:ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 2ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 3ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products 4Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 2Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies' Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 2Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 3Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 4Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 5Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 6Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 7Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 8Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 9Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 10Human Genome Sciences Announces Fourth Quarter and Full Year 2007 Financial Results and Recent Progress 11
(Date:8/20/2014)... Arizona State University, the Wellcome Trust Sanger Institute and ... isolated Mycobacterium pinnipedii from skeletons found in ... pathogen is a relative of the TB bacterium that ... today. These researchers assume that seals carried the pathogens ... sea lions was unexpected" comments Sebastien Gagneux, from the ...
(Date:8/20/2014)... Calif., August 19, 2014 -- Bay Area Lyme Foundation, ... and simple to cure, applauds new research published in ... Ticks and Tick-borne Diseases . The findings ... California are active throughout the year, making the threat ... researchers at California Department of Public Health (CDPH) Vector-borne ...
(Date:8/20/2014)... have suffered concussions ready to return to action? A ... school athletes who head back on the field with ... in their abilities to simultaneously walk and do simple ... in their balance and/or altered walking speed, was found ... had returned to activity in less than a month. ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... research from Rice University, Baylor College of Medicine (BCM) and ... of flow in the small blood vessels of the heart ... and form dangerous blood clots. The scientists were surprised to ... shape for up to five hours before returning to their ...
... Department of Energy,s National Renewable Energy Laboratory (NREL) eases and ... industry: determining cell wall chemistry to find plants with ideal ... thoroughly analyze hundreds of biomass samples a day and give ... pursuing. Analysis of a sample that previously took two weeks ...
... VA As the Colorado River winds through the Colorado ... of sediment. This sediment which once left the river,s ... Colorado "the reddish river" is a vital component to ... of the Hoover and Glen Canyon dams, which trap the ...
Cached Biology News:Stressed proteins can cause blood clots for hours 2Stressed proteins can cause blood clots for hours 3Biomass analysis tool is faster, more precise 2Biomass analysis tool is faster, more precise 3Biomass analysis tool is faster, more precise 4Biomass analysis tool is faster, more precise 5
... Rat Antibody to Human CD66 ... is expressed by human neutrophils and ... carcinoma. Clone YTH71.3 reacts with transfectants ... are CEA subfamily members(2). ...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Request Info...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: